Supplementary Appendix
|
|
- Bertram Brett Holmes
- 5 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015;373: DOI: /NEJMoa
2 SUPPLEMENTARY APPENDIX Antisense Inhibition of APOC3 in Patients with Hypertriglyceridemia Gaudet D, et al. Table of Contents Study Investigators. 2 Additional Details on Methods... 3 Figure S1. Flow of study participants... 6 Figure S2. Association between total plasma TG and APOC3 levels for all patients by dose group, and by patients treated with 300 mg ISIS , in the (A, B) monotherapy, (C, D) add-on to fibrate, and (E, F) both cohorts Figure S3. Mean percentage change from baseline over time in the ISIS add-on to fibrate cohort by dose group for (A) APOC3, (B) triglyceride, and (C) HDL-cholesterol Figure S4. Individual TG levels at end of treatment in the ISIS add-on to fibrate cohort by (A) percent change from baseline, and (B) absolute level Table S1. Patient disposition (A) Baseline characteristics, (B) Heterozygous loss-of function LPL mutations, and (C) APOE genotypes Table S2. Correlations between APOC3 and total TG for the absolute and percent change from baseline values over time Table S3. Effect of ISIS treatment on primary and secondary outcomes Table S4. Effect of ISIS treatment on VLDL-apoB and LDL-apoB levels Table S5. Effect of ISIS treatment on (A) Chylo/VLDL, (B) LDL and (C) HDL particles. 18 Table S6. Adverse events in the ISIS (A) monotherapy and (B) add-on to fibrate cohorts Table S7. Percentage of injections with local cutaneous reactions in the ISIS (A) monotherapy and (B) add-on to fibrate cohorts References P a g e
3 Study Investigators (NCT , ISIS CS2) Daniel Gaudet, MD, PhD, study principle investigator of Université de Montréal and Ecogene- 21Clinical Research Center (Chicoutimi Qc, CAN) Business Associate Principal Investigators of CTMG, Inc., a Site-Specific Research Organization (SSRO): Mark R. Cervi, MD of CTMG, Inc. (Greenville NC) Natalie A. Doyle, MD of CTMG, Inc. (Wilson NC) Gary H. Heck, DO of CTMG, Inc. (Kinston NC) Charles E. Jahrsdorfer, MD of CTMG, Inc. (Greenville NC) Enrique V. Marana, MD of CTMG, Inc. (Farmville NC) Richard Z. Shultzaberger, MD of CTMG, Inc. (Greenville NC) 2 P a g e
4 Additional Details on Methods STUDY DRUG ISIS (5 -AGCTTCTTGTCCAGCTTTAT-3 ) is a second-generation antisense inhibitor of APOC3 synthesis that incorporates several chemical modifications to improve potency, duration of action, and tolerability. All of the internucleotide phosphates are chemically modified with a phosphorothioate substitution, in which one of the non-bridging oxygen atoms is substituted with sulfur. Additionally the drug incorporates five 2 -O-(2-methoxyethyl) (2 -MOE) modified ribonucleosides (underlined) at the 3 and 5 ends while retaining ten 2 -O-deoxyribonucleosides within the central portion of the molecule. ISIS was supplied by Isis Pharmaceuticals Inc. (Carlsbad, CA, USA) in 2-mL stoppered glass vials as a 1-mL solution (200 mg/ml) for single use only. Patients, investigator(s), and study staff were blinded to the treatment assignment, except for the pharmacist who prepared the drug. Placebo was 0.9% sterile saline. ISIS , or placebo, was administered as a single subcutaneous injection once a week for 13 weeks at the specified dose. STUDY PARTICIPANTS Study participants were 18 years old, had a body mass index (BMI) 40 kg/m 2, and had no current diagnosis or history of endocrine, hematologic, renal, hepatic, metabolic, psychiatric, neurologic, pulmonary, or cardiovascular disease, including any condition that pre-disposed to secondary hyperlipidemia, such as uncontrolled diabetes mellitus or hypothyroidism, nor were they taking drugs that increase TG levels. After a 6 to 8-week diet run-in period, eligible patients not on a TG-lowering therapy had fasting TG 350 mg/dl (4.0 mmol/l) and 2000 mg/dl (22.6 mmol/l), and those on a stable dose of fibrate had fasting TG 225 mg/dl (2.5 mmol/l) and 2000 mg/dl (22.6 mmol/l). STUDY DESIGN A randomized, double-blind, placebo-controlled, dose-ranging study design was used to evaluate the effects of ISIS in patients with severe or uncontrolled hypertriglyceridemia. Eligible patients not on fibrate therapy were assigned to the ISIS monotherapy cohort, and those on a stable dose of fibrate were assigned to the add-on to fibrate cohort. ISIS monotherapy patients were randomized equally (1:1:1) to receive doses of 100, 200, and or 300 mg in a 3:1 active to placebo ratio. Eligible patients on a fibrate were randomized equally (1:1) to receive 200 or 300 mg ISIS , and in a 2:1 active-to-placebo ratio. Patients received 13 doses of study 3 P a g e
5 drug by SC injection once a week for 13 weeks, and then were followed in post-treatment evaluation for 13 weeks. All enrolled patients received diet/alcohol counseling and monitoring for the duration of study participation. Patients were allowed to continue ongoing stable doses of statin therapy and/or oral antidiabetic medication. Alcohol consumption was not allowed for 48 hours prior to visits where lipids were measured. In addition, patients were provided a standardized pre-cooked meal for the dinner (after which they remained fasted for at least 10 hours) prior to these visits. Samples were collected before dosing during the treatment period. OUTCOMES The primary outcome was the percent change in fasting total APOC3 levels from baseline to the end of treatment (average of Day 85 and Day 92). Secondary outcomes included percent change in fasting TG, total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol (density gradient <1.006 g/ml), non-hdl cholesterol, total apolipoprotein B (apob), apolipoprotein B-48 (apob-48) and VLDL- APOC3 (density gradient <1.006 g/ml), from baseline to the end of treatment, as well as over time for APOC3 and these other listed parameters. Safety was assessed by determining the incidence, severity, and dose relationship of adverse events (AEs) and changes in laboratory parameters. Safety laboratory evaluations included routine hematology, blood chemistry, urinalysis, and coagulation parameters. Other assessments included a physical examination, a 12 lead electrocardiogram, and vital signs. LIPID MEASUREMENTS Fasted blood samples were collected for measurement of lipid parameters at baseline, on Day 8 and then weekly to every other week during the treatment period (immediately prior to administration of ISIS ), and on Days 92, 99, 127 and 176 during the post-treatment follow-up period. Total plasma APOC3, chylomicron/vldl APOC3 (density gradient <1.006 g/ml), TGs, total cholesterol, HDL cholesterol (precipitated), non-hdl cholesterol (calculated), LDL cholesterol (isolated by ultracentrifugation), chylomicron/vldl cholesterol (density gradient <1.006 g/ml), and apob-48 levels were determined at MedPace Reference Labs (Cincinnati, OH). Triglycerides and cholesterol were measured by standard enzyme-based colorimetric assays. APOC3, total apob and apob-48 were measured by rate nephelometry. Non-HDL cholesterol was calculated. VLDL and LDL 4 P a g e
6 fractions were isolated from samples by ultracentrifugation, and then assayed for apolipoprotein B content (VLDL-apoB and LDL-apoB) at Ecogene-21 (Chicoutimi, QC Canada). GENOTYPING LPL and APOE genotyping were performed at Ecogene-21 (Chicoutimi, QC Canada). STATISTICAL ANALYSIS Primary and secondary pharmacodynamic outcomes were analyzed per protocol. These analyses included all patients who received at least 9 doses of study drug and had no significant protocol deviations that would be expected to affect the outcome measures. Analyses evaluating safety of the intervention included all randomized patients who received at least one dose of study drug. The primary analysis compared the percent change in fasting total APOC3 levels from baseline to the end of treatment (primary outcome) in the 300 mg dose group of the monotherapy cohort, compared to that of the placebo group. Secondary analyses included comparisons of the primary outcome for other dose groups to the placebo group of each cohort. Similar analyses were done for the secondary outcomes. These latter analyses were exploratory in nature and performed without adjustment for multiple comparisons. Least squares means were estimated from a mixed-effect model repeated-measures analysis of a modified intent-to-treat population, which included all dosed patients with at least one post-baseline APOC3 measurement. P-values were determined from the Wilcoxon Rank Sum test or t-test depending on normality of the data. Normality was determined using the Kolmogorov-Smirnov test. All statistical tests were unpaired and two-sided, with a significance level of 0.05 for the primary analysis. Post-hoc correlation coefficients (r) were derived from Pearson product-moment correlations. Software utilized for the analyses was SAS version 9.2 or higher (SAS Institute). Sample size was based on a standard deviation of the percent change in total APOC3 of approximately 46% as estimated from prior clinical experience. Under these assumptions, there was estimated to be at least 80% power to detect a 45% difference in total APOC3 between ISIS and placebo group at an alpha level of 0.05, assuming 50% reduction in patients receiving ISIS and 5% in the placebo group. 5 P a g e
7 Figure S1. Flow of Study Participants Abbreviations: w/c, withdrew consent; AE, adverse event; PD, pharmacodynamics. Analysis of PD outcomes was performed on the per-protocol population as defined in the methods section. * Patients assigned to ISIS monotherapy were randomized equally (1:1:1) to receive doses of 100, 200 or 300 mg, and then 3:1 active to placebo. Patients assigned to ISIS add-on to fibrate were randomized equally (1:1) to receive doses of 200 or 300 mg, and then 2:1 active-to-placebo. Principle reason for dose discontinuation: injection site reaction (moderate); abdominal distension (severe); mononucleosis (moderate); musculoskeletal pain (mild); ** serum sickness-like reaction (moderate); fatigue (mild). 6 P a g e
8 Figure S2. Association between total plasma TG and APOC3 levels for all patients by dose group, and by patients treated with 300 mg ISIS , in the (A, B) monotherapy, (C, D) add-on to fibrate, and (E, F) both cohorts. 7 P a g e
9 Figure S3. Mean percentage change from baseline over time in the ISIS add-on to fibrate cohort by dose group for (A) APOC3, (B) triglyceride, and (C) HDL-cholesterol. Solid blue triangles indicate dosing days. 8 P a g e
10 Figure S4. Individual TG levels at end of treatment in the ISIS add-on to fibrate cohort by (A) percent change from baseline, and (B) absolute level. 9 P a g e
11 Table S1. Patient Disposition. (A) Baseline characteristics, (B) Heterozygous loss-of-function LPL mutations, and (C) APOE genotypes A ISIS Monotherapy ISIS Add-on to Fibrate * Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Characteristic (N=16) (N=13) (N=15) (N=13) (N=8) (N=8) (N=12) Gender, F:M 3:13 5:8 1:14 5:8 4:4 2:6 5:7 Age, years 48.6 ± ± ± ± ± ± ±13.8 BMI, kg/m ± ± ± ± ± ± ±4.6 Statins, n (%) 4 (25.0) 6 (46.2) 4 (26.7) 5 (38.5) 4 (50.0) 4 (50.0) 4 (33.3) Maximal Statin 2 (12.5) 2 (15.4) 2 (13.3) 2 (15.4) 1 (12.5) 4 (50.0) 0 (0.0) Triglycerides, mg/dl ± ± ± ± ± ± ±207.4 Median (IQR) 459 (356, 582) 558 (351, 649) 588 (464, 858) 566 (422, 702) 475 (253, 602) 272 (230, 295) 302 (246, 451) HDL-C, mg/dl 33.0 ± ± ± ± ± ± ±11.5 LDL-C, mg/dl ± ± ± ± ± ± ±27.7 Results presented are based on analysis of the Safety population. Values are the mean ± standard deviation, except where indicated. IQR denotes interquartile range, Q1 and Q3. * 25 of 28 (89%) patients were on stable doses of fenofibrate (median daily dose = 145 mg); 3 of 28 (11%) patients were on stable doses of gemfibrozol (median daily dose = 1200 mg). Maximal statin (total daily dose): 40 mg and above of rosuvastatin, atorvastatin, pravastatin, or simvastatin. 10 P a g e
12 Table S1 (cont). B ISIS Monotherapy ISIS Add-on to Fibrate LPL Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Mutation, n (%) (N=16) (N=13) (N=15)* (N=13) (N=8) (N=8) (N=12) Heterozygous mutation 4 (25.0) 5 (38.5) 1 (6.7) 4 (30.8) 2 (25.0) 2 (25.0) 2 (16.7) P207L 2 (12.5) 4 (30.8) 1 (6.7) 2 (15.4) 1 (12.5) 1 (12.5) 2 (16.7) D9N 3 (18.8) 1 (7.7) 0 (0.0) 1 (7.7) 0 (0.0) 1 (12.5) 1 (8.3) G188E 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) N291S 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.7) 1 (12.5) 0 (0.0) 0 (0.0) Results are based on analysis of the Safety population. *Data not available for 2 patients; Data not available for 3 patients. C ISIS Monotherapy ISIS Add-on to Fibrate APOE Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Genotype, n (%) (N=16) (N=13) (N=15)* (N=13) (N=8) (N=8) (N=12) E2/2 1 (6.3) 1 (7.7) 0 (0.0) 2 (15.4) 3 (37.5) 1 (12.5) 1 (8.3) E2/3 3 (18.8) 2 (15.4) 2 (13.3) 1 (7.7) 2 (25.0) 0 (0.0) 2 (16.7) E2/4 0 (0.0) 0 (0.0) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) E3/3 6 (37.5) 3 (23.1) 4 (26.7) 1 (7.7) 1 (12.5) 4 (50.0) 3 (25.0) E3/4 6 (37.5) 7 (53.8) 5 (33.3) 6 (46.2) 1 (12.5) 3 (37.5) 2 (16.7) E4/4 0 (0.0) 0 (0.0) 0 (0.0) 3 (23.1) 1 (12.5) 0 (0.0) 1 (8.3) Results are based on analysis of the Safety population. *Data not available for 2 patients; Data not available for 3 patients. 11 P a g e
13 Table S2. Correlations between APOC3 and total TG for the absolute and percent change from baseline values over time. Monotherapy Add-on to Fibrate Both Cohorts APOC3 vs TG All Patients 300 mg ISIS All Patients 300 mg ISIS All Patients 300 mg ISIS Absolute % Change P a g e
14 Table S3. Effect of ISIS treatment on primary and secondary outcomes ISIS Monotherapy ISIS Add-on to Fibrate Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Parameter (N=16) (N=11) (N=13) (N=11) (N=8) (N=8) (N=10) APOC3, mg/dl Baseline 22.2 ± ± ± ± ± ± ±5.9 Endpoint 21.9 ± ± ± ± ± ± ±2.1 % Change 4.2 ± ±32.0* ± ± ± ± ±13.0 LS Mean ±SE 4.2 ± ± ± ± ± ± ±5.3 Triglycerides, mg/dl Baseline ± ± ± ± ± ± ±227.8 Median (IQR) 459 (356, 582) 558 (351, 825) 588 (464, 717) 566 (355, 702) 475 (253, 602) 272 (230, 295) 271 (241, 459) Endpoint ± ± ± ± ± ± ±60.9 Median (IQR) 456 (343, 640) 277 (226, 394) 180 (157, 262) 120 (115, 185) 338 (290, 394) 120 (103, 172) 116 (91, 191) % Change 20.1 ± ±56.8* ± ± ± ± ±8.9 Median (IQR) 12.1 (-24.6, 28.9) (-71.5, -7.0) (-79.5, -43.4) (-82.8, -67.0) (-29.8, 9.7) (-63.5, -39.8) (-70.7, -54.6) LS Mean ±SE 20.1 ± ±15.1* ± ± ± ± ± P a g e
15 ISIS Monotherapy ISIS Add-on to Fibrate Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Parameter (N=16) (N=11) (N=13) (N=11) (N=8) (N=8) (N=10) Total Cholesterol, mg/dl Baseline ± ± ± ± ± ± ±38.8 Endpoint ± ± ± ± ± ± ±54.7 % Change 4.1 ± ± ± ± ± ± ±23.2 LS Mean ±SE 4.1 ± ± ± ± ± ± ±5.7 HDL-C, mg/dl Baseline 33.0 ± ± ± ± ± ± ±12.3 Endpoint 33.2 ± ± v ± ± ± ±19.9 % Change 0.7 ± ± ± ± ± ±32.0* ±23.7 LS Mean ±SE 0.7 ± ± ± ± ± ± ±8.2 Non-HDL-C, mg/dl Baseline ± ± ± ± ± ± ±44.4 Endpoint ± ± ± ± ± ± ±64.2 % Change 6.2 ± ± ± ± ± ± ±28.8 LS Mean ±SE 6.2 ± ± ± ± ± ± ± P a g e
16 ISIS Monotherapy ISIS Add-on to Fibrate Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Parameter (N=16) (N=11) (N=13) (N=11) (N=8) (N=8) (N=10) LDL-C, mg/dl Baseline ± ± ± ± ± ± ±26.2 Endpoint ± ± ± ± ± ± ±62.1 % Change 10.8 ± ±39.0* 79.4 ± ±177.3* 5.3 ± ± ±49.7 LS Mean ±SE 10.8 ± ± ± ± ± ± ±12.4 VLDL-C, mg/dl Baseline ± ± ± ± ± ± ±48.2 Endpoint 96.5 ± ± ± ± ± ± ±15.3 % Change 6.3 ± ±41.8* ± ± ± ±22.5* ±21.6* LS Mean ±SE 6.3 ± ± ± ± ± ± ±10.1 VLDL-APOC3, mg/dl Baseline 11.6 ± ± ± ± ± ± ±2.6 Endpoint 12.1 ± ± ± ± ± ± ±1.0 % Change 21.0 ± ±65.6* ± ± ± ± ±11.4 LS Mean ±SE 21.0 ± ± ± ± ± ± ± P a g e
17 ISIS Monotherapy ISIS Add-on to Fibrate Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Parameter (N=16) (N=11) (N=13) (N=11) (N=8) (N=8) (N=10) Total ApoB, mg/dl Baseline ± ± ± ± ± ± ±27.0 Endpoint ± ± ± ± ± ± ±45.8 % Change 3.9 ± ± ± ± ± ± ±27.7 LS Mean ±SE 3.9 ± ± ± ± ± ± ±6.9 ApoB-48, mg/dl Baseline 0.7 ± ± ± ± ± ± ±0.2 Endpoint 1.0 ± ± ± ± ± ± ±0.2 % Change 64.5 ± ±45.5* ± ± ± ± ±20.1 Results presented are based on the Per-Protocol population, except for the LS mean percent change from baseline results. Values are the means ± standard deviations in mg/dl, except where indicated. Baseline is defined as the Day -8 value. Endpoint represents the average of the Day 85 and Day 92 values. Percent (%) change represents from Baseline to Endpoint. IQR denotes interquartile range, Q1 and Q3; LS, least squares; SE, standard error. To convert apolipoprotein values (APOC3, VLDL-APOC3, ApoB, and ApoB-48) to g/l multiply by 0.01; to convert triglyceride (TG) values to mmol/l multiply by ; to convert cholesterol (C) values to mmol/l, multiply by P-value * <0.05; <0.01; < P a g e
18 Table S4. Effect of ISIS treatment on VLDL-apoB and LDL-apoB Levels ISIS Monotherapy ISIS Add-on to Fibrate ApoB, mg/dl Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Mean ±SD (N=16) (N=11) (N=13) (N=11) (N=8) (N =8) (N =10) VLDL-apoB Baseline 20.1 ± ± ± ± ± ± ±11.8 Endpoint 16.5 ± ± ± ± ± ± ±4.0 % Change -7.6 ± ± ± ± ± ± ±370.2* Median (IQR) (-44.3, 21.4) (-51.7, 13.8) (-82.4, 3.1) (-77.3, -50.0) (-31.1, -14.8) (-75.0, -30.0) (-80.6, -42.9) LDL-apoB Baseline 95.8 ± ± ± ± ± ± ±23.2 Endpoint 95.6 ± ± ± ± ± ± ±44.0 % Change 8.5 ± ± ± ± ± ± ±32.0 Median (IQR) 4.9 (-13.4, 16.2) 15.7 (8.9, 31.9) 28.9 (15.3, 53.8) 41.8 (-2.7, 81.5) 6.1 (-21.4, 17.6) 2.7 (-15.3, 16.8) -1.7 (-4.5, 30.6) Results presented are based on analysis of the Per-Protocol population. Values are the means ± standard deviations in mg/dl, except for % change which shows both the mean ±standard deviation and median (interquartile range) results. Baseline is defined as the average of Day -8 and Day -1, or Day 1, pre-dose results. Endpoint represents the average of the Day 85 and Day 92 values. To convert apolipoprotein values to g/l multiply by P-values were determined for percent change from baseline at end point, vs placebo (* <0.05; <0.01; <0.001). 17 P a g e
19 Table S5. Effect of ISIS treatment on lipoprotein particle size: Chylomicron/VLDL, LDL and HDL particles ISIS Monotherapy ISIS Add-on to Fibrate Size, nm Placebo 100 mg 200 mg 300 mg Placebo 200 mg 300 mg Median (Q1,Q3) (N=16) (N=11) (N=13) (N=11) (N=8) (N=8) (N=10) Chylo/VLDL-P Baseline 63.4 (58.1, 71.1) 58.1 (51.2, 68.4) 66.8 (62.1, 71.1) 64.2 (61.5, 70.3) 56.9 (54.7, 58.8) 58.2 (52.8, 62.1) 57.7 (49.5, 62.9) Day (56.2, 70.9) 56.0 (48.2, 61.6) 56.7 (49.5, 60.6) 53.8 (48.6, 57.1) 53.8 (50.0, 58.0) 49.7 (45.3, 59.4) 51.5 (48.1, 55.9) Change 1.0 (-3.5, 3.1) -4.0 (-9.1, 2.6) (-15.3, -4.2) (-18.5, -6.3) -3.6 (-5.3, -0.1) -7.1 (-8.7, 0.0) -4.2 (-14.1, -1.2) LDL-P Baseline 19.6 (19.6, 19.7) 19.6 (19.4, 19.6) 19.5 (19.5, 19.6) 19.6 (19.6, 19.6) 19.7 (19.6, 19.8) 19.7 (19.7, 20.0) 19.7 (19.6, 19.8) Day (19.5, 19.6) 19.6 (19.6, 20.0) 20.3 (19.8, 20.6) 20.1 (19.7, 20.5) 19.7 (19.6, 20.1) 20.6 (20.3, 20.6) 20.3 (19.8, 21.1) Change -0.1 (-0.1, 0.0) 0.2 (0.0, 0.3) 0.7 (0.2, 1.1) 0.4 (0.1, 0.8) 0.0 (-0.1, 0.5) 0.6* (0.5, 0.9) 0.7* (0.3, 1.3) HDL-P Baseline 8.9 (8.6, 9.2) 8.9 (8.7, 9.1) 8.8 (8.8, 9.1) 8.8 (8.5, 9.1) 8.7 (8.4, 8.8) 8.6 (8.5, 8.7) 8.8 (8.6, 9.0) Day (8.7, 9.2) 8.8 (8.7, 9.2) 8.5 (8.5, 8.9) 8.7 (8.6, 8.8) 8.7 (8.5, 8.8) 8.5 (8.3, 8.8) 9.1 (8.6, 9.2) Change 0.0 (-0.1, 0.2) 0.1 (-0.4, 0.2) -0.3 (-0.5, -0.1) -0.1 (-0.6, 0.4) 0.0 (0.0, 0.2) 0.0 (-0.1, 0.2) 0.3 (-0.4, 0.4) Particle parameters were derived by NMR spectroscopy analysis (LipoScience Inc., Raleigh NC). 1 Values shown are the median (interquartile range). Change is from baseline to Day 92. Chylo/VLDL-P denotes chylomicron/very-low-density lipoprotein particle; LDL-P, low-density lipoprotein particle; HDL-P, high-density lipoprotein particle. P-values * <0.05; <0.01; <0.001 (vs placebo). 18 P a g e
20 Table S6. Adverse events in the ISIS (A) monotherapy and (B) add-on to fibrate cohorts* A 100 mg 200 mg 300 mg Total Placebo ISIS ISIS ISIS ISIS Preferred Term, n (%) (N=16) (N=13) (N=15) (N=13) (N=41) Fatigue 1 (6.3) 2 (15.4) 2 (13.3) 2 (15.4) 6 (14.6) Musculoskeletal pain 0 (0.0) 0 (0.0) 2 (13.3) 2 (15.4) 4 (9.8) Nausea 0 (0.0) 0 (0.0) 0 (0.0) 4 (30.8) 4 (9.8) Chills 0 (0.0) 1 (7.7) 1 (6.7) 1 (7.7) 3 (7.3) Myalgia 0 (0.0) 1 (7.7) 1 (6.7) 1 (7.7) 3 (7.3) B 200 mg 300 mg Total Placebo ISIS ISIS ISIS Preferred Term, n (%) (N=8) (N=8) (N=12) (N=20) Diarrhoea 1 (12.5) 2 (25.0) 0 (0.0) 2 (10.0) Abdominal pain upper 0 (0.0) 0 (0.0) 2 (16.7) 2 (10.0) Fatigue 0 (0.0) 1 (12.5) 1 (8.3) 2 (10.0) Feeling of Relaxation 0 (0.0) 0 (0.0) 2 (16.7) 2 (10.0) * Adverse events related or possibly related to study drug; events at the injections site are excluded (see Table S7). 19 P a g e
21 Table S7. Percentage of injections with local cutaneous reactions in the ISIS (A) monotherapy and (B) add-on to fibrate cohorts* A 100 mg 200 mg 300 mg Total Placebo ISIS ISIS ISIS ISIS % Injections (N=16) (N=13) (N=15) (N=13) (N=41) Mean (SD) 0.0 (0.0) 11.5 (28.0) 5.4 (7.4) 24.7 (30.5) 13.4 (24.5) Median (Q1, Q3) 0.0 (0.0, 0.0) 0.0 (0.0, 7.7) 0.0 (0.0, 12.5) 15.4 (0.0, 38.5) 0.0 (0.0, 15.4) B 200 mg 300 mg Total Placebo ISIS ISIS ISIS % Injections (N=8) (N=8) (N=12) (N=20) Mean (SD) 0.0 (0.0) 19.2 (31.3) 11.7 (16.4) 14.7 (23.0) Median (Q1, Q3) 0.0 (0.0, 0.0) 3.8 (0.0, 34.6) 3.8 (0.0, 19.2) 3.8 (0.0, 19.2) * Local cutaneous reactions are adverse events at the injection site defined as erythema, swelling, pruritus, pain and/or tenderness, which started on the day of injection and persisted for two days or more. 20 P a g e
22 References 1. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: P a g e
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Andres Digenio, MD, PhD; Richard L. Dunbar, MD; Veronica J. Alexander,
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEfficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies
Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Michael J. Koren, 1 Evan A. Stein, 2 Eli M. Roth, 3 James M. McKenney, 4 Dan Gipe,
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEffect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationA Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia Marina Cuchel, MD, PhD University of Pennsylvania, Philadelphia,
More informationEfficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study
Efficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study Erik Stroes, 1 John Guyton, 2 Michel Farnier, 3 Norman Lepor, 4 Fernando Civeira,
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
2. SYNOPSIS Title of Study: An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of and a Single Dose of Rosuvastatin (Crestor ), to Assess the Dose Proportionality of,
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationEffects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome A randomized, double-blind,
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationN-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP
Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationCoverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests
Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationAMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study
AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study HE Bays, 1 CM Ballantyne, 2 JJ Kastelein, 3 E Stein, 4 JL Isaacsohn,
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationAlirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia
Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Alirocumab (Praluent,
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationRelationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome
ORIGINAL INVESTIGATION Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome Jacob J. Clarenbach, Scott M. Grundy, Natalia Palacio, and Gloria Lena Vega Low-density
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Digenio A, et al. Table of Contents Detailed Methods for Clinical
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin
More informationSimvastatin With or Without Ezetimibe in Familial Hypercholesterolemia
Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia The trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationThe Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures
Miami Cardiac & Vascular Institute Cardiovascular Disease Prevention 15th Annual Symposium February 16, 2017 Nobu Eden Roc Hotel, Miami Beach, Florida. The Role of Apolipoprotein CIII in Coronary Artery
More informationSYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study:
SYNOPSIS Title of the study: Investigator(s): A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationThe Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia
The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationLipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?
Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history
More informationPCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?
PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationEarly Clinical Development #1 REGN727: anti-pcsk9
Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationFAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) Dr. Joseph L. Witztum Distinguished Professor of Medicine, Department of Medicine & Director, Atherosclerosis Research Group, University of California, San Diego
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
The new england journal of medicine Original Article Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia Daniel Gaudet, M.D., Ph.D., Veronica J. Alexander, Ph.D., Brenda
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald, PhD Co-authors: Amy Simon 1, Suellen White 1,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationThe role of mipomersen therapy in the treatment of familial hypercholesterolemia
Reviews: Clinical Trial Outcomes The role of mipomersen therapy in the treatment of familial hypercholesterolemia Clin. Invest. (2012) 2(10), 1033 1037 Familial hypercholesterolemia (FH) is a genetic disorder
More informationWilliam Campbell Cromwell, MD Curriculum Vitae
William Cromwell, MD Medical Director Division of Lipoprotein Disorders Presbyterian Center for Preventive Cardiology Presbyterian Cardiovascular Institute Adjunct Associate Professor Wake Forest University
More informationIONIS-ANGPTL3-L, an antisense inhibitor to
IIS-AGPTL3-L Rx, an antisense inhibitor to angiopoietin-like protein 3 [AGPTL3] reduces plasma AGPTL3 and lipids in healthy volunteers with elevated triglycerides Teresa A. Brandt 1, Li-Jung Tai 1, Joseph
More informationWalter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI
Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationSITA 100 mg (n = 378)
Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)
More information